Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12)

Trial Profile

A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms ZUMA-12
  • Sponsors Kite Pharma

Most Recent Events

  • 04 Dec 2024 Timeframe for primary endpoint changed .
  • 12 Dec 2023 Results of updated efficacy and safety outcomes from ZUMA-12 in all patients treated with axi-cel after a median follow-up to 40 months,presented at the 65th American Society of Hematology Annual Meeting and Exposition.
  • 11 Dec 2023 According to Kite Pharma media release, data from this trial presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top